The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Interaction of IL-13 and C10 in the Pathogenesis of Bleomycin-Induced Pulmonary Fibrosis
Abstract
The initial stimulus for inflammatory cell recruitment and the mechanisms responsible for the perpetuation and evolution of chronic inflammation, granulation tissue formation, and fibrosis have not been fully elucidated. Although interleukin (IL)-13, a Th2 cytokine, has been shown to have direct effects on fibroblasts that support fibroproliferation, it is also a potent inducer of a novel CC chemokine, C10, which is chemotactic for mononuclear phagocytes. The macrophage/mononuclear phagocyte has been shown to have a role in the pathogenesis of pulmonary fibrosis, serving as an important source of growth factors that regulate extracellular matrix synthesis. In this study we demonstrate that IL-13 and C10 are elevated in the pathogenesis of bleomycin-induced pulmonary fibrosis. Neutralization of IL-13, but not IL-4, attenuated bleomycin-induced pulmonary fibrosis and levels of C10, suggesting that IL-13 has an important role in the development of pulmonary fibrosis. IL-13 is a potent inducer of C10 in vivo, and neutralization of C10 attenuated bleomycin-induced pulmonary fibrosis and intrapulmonary macrophage numbers. This suggests that IL-13 has a role in the development of pulmonary fibrosis that is independent of its direct effect on fibroblasts and is evidence for an interaction between Th2 cytokines and specific CC chemokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Singer, A. J., & Clark, R. A. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411006 · Cited by 6,106
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940
Self-citationZiesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.-H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411703 · Cited by 586
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts
Oriente, A., Fedarko, N. S., Pacocha, S. E., Huang, S.-K., Lichtenstein, L. M., & Essayan, D. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35380-7 · Cited by 230
Piguet, P. F., Vesin, C., Grau, G. E., & Thompson, R. C. (1993) · Cytokine · doi:10.1016/1043-4666(93)90024-y · Cited by 215
IL-12 attenuates bleomycin-induced pulmonary fibrosis
Keane, M. P., Belperio, J. A., Burdick, M. D., & Strieter, R. M. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.281.1.l92 · Cited by 146
Self-citation
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
“fumigatus conidia [91] or bleomycin [49].”
BackgroundFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis
Phillips, R. J., Burdick, M. D., Hong, K., Lutz, M. A., Murray, L. A., Xue, Y. Y., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420997 · Cited by 1,079
Self-citationFichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K., & Kitani, A. (2006) · Nature Medicine · doi:10.1038/nm1332 · Cited by 889
Pulmonary fibrosis: pathogenesis, etiology and regulation
Wilson, M. S., & Wynn, T. A. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.85 · Cited by 822
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
IL-4 and IL-13 signaling in allergic airway disease
Gour, N., & Wills-Karp, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.014 · Cited by 490
CCR2-Mediated Recruitment of Fibrocytes to the Alveolar Space after Fibrotic Injury
Moore, B. B., Kolodsick, J. E., Thannickal, V. J., Cooke, K., Moore, T. A., Hogaboam, C., Wilke, C. A., & Toews, G. B. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62289-4 · Cited by 441
Immune mechanisms in pulmonary fibrosis
Kolahian, S., Fernandez, I. E., Eickelberg, O., & Hartl, D. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0121tr · Cited by 349
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382
Lee, C. G., Cho, S. J., Kang, M. J., Chapoval, S. P., Lee, P. J., Noble, P. W., Yehualaeshet, T., Lu, B., Flavell, R. A., Milbrandt, J., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040104 · Cited by 369
Self-citationTakeshita, Y., & Ransohoff, R. M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01127.x · Cited by 325
Phillips, R. J., Mestas, J., Gharaee-Kermani, M., Burdick, M. D., Sica, A., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500963200 · Cited by 323
Self-citationDepletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer
Keane, M. P., Belperio, J. A., Xue, Y. Y., Burdick, M. D., & Strieter, R. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2853 · Cited by 305
Self-citationImmune dysregulation as a driver of idiopathic pulmonary fibrosis
Shenderov, K., Collins, S. L., Powell, J. D., & Horton, M. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143226 · Cited by 295
New Mechanisms of Pulmonary Fibrosis
Strieter, R. M., & Mehrad, B. (2009) · Chest · doi:10.1378/chest.09-0510 · Cited by 284
The pathogenesis of idiopathic pulmonary fibrosis
Coward, W. R., Saini, G., & Jenkins, G. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379801 · Cited by 272
Fibrosis Related Inflammatory Mediators: Role of the IL‐10 Cytokine Family
Sziksz, E., Pap, D., Lippai, R., Béres, N. J., Fekete, A., Szabó, A. J., & Vannay, Á. (2015) · Mediators of Inflammation · doi:10.1155/2015/764641 · Cited by 265
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Su, S., Zhao, Q., He, C., Huang, D., Liu, J., Chen, F., Chen, J., Liao, J.-Y., Cui, X., Zeng, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms9523 · Cited by 253
T cells in systemic sclerosis: a reappraisal
O'Reilly, S., Hugle, T., & van Laar, J. M. (2012) · Rheumatology · doi:10.1093/rheumatology/kes090 · Cited by 218
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury
Cortijo, J., Iranzo, A., Milara, X., Mata, M., Cerdá‐Nicolás, M., Ruiz‐Saurí, A., Tenor, H., Hatzelmann, A., & Morcillo, E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00041.x · Cited by 114
Evidence for a Functional Thymic Stromal Lymphopoietin Signaling Axis in Fibrotic Lung Disease
Datta, A., Alexander, R., Sulikowski, M. G., Nicholson, A. G., Maher, T. M., Scotton, C. J., & Chambers, R. C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300588 · Cited by 73
“Although the contribution of inflammation to disease initiation and progression in IPF remains unclear (38), current evidence supports the notion that type 2 cytokines, in particular IL-13, may contribute to fibrotic responses by amplifying the dysregulated epithelial–mesenchymal cross-talk, which is central to this c…”
BackgroundFritz, D. K., Kerr, C., Fattouh, R., Llop-Guevara, A., Khan, W. I., Jordana, M., & Richards, C. D. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903476 · Cited by 69
Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis
Singh, B., Kasam, R. K., Sontake, V., Wynn, T. A., & Madala, S. K. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00184.2017 · Cited by 48
Metadata
- Authors
- Belperio, J. A., Dy, M., Burdick, M. D., Xue, Y. Y., Li, K., Elias, J. A., & Keane, M. P.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10
- Volume
- 27
- Issue
- 4
- Pages
- 419-427
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W2027314854
- Cited by
- 232
- References
- 6
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.